University of Surrey

Test tubes in the lab Research in the ATI Dance Research

In Vitro Evaluation of Eudragit Matrices for Oral Delivery of BCG Vaccine to Animals

Saleem, Imran, Coombes, Allan G. A. and Chambers, Mark A. (2019) In Vitro Evaluation of Eudragit Matrices for Oral Delivery of BCG Vaccine to Animals Pharmaceutics, 11 (6).

[img]
Preview
Text
pharmaceutics-11-00270.pdf - Version of Record
Available under License Creative Commons Attribution.

Download (2MB) | Preview

Abstract

Bacillus Calmette–Guérin (BCG) vaccine is the only licensed vaccine against tuberculosis (TB) in humans and animals. It is most commonly administered parenterally, but oral delivery is highly advantageous for the immunisation of cattle and wildlife hosts of TB in particular. Since BCG is susceptible to inactivation in the gut, vaccine formulations were prepared from suspensions of Eudragit L100 copolymer powder and BCG in phosphate-buffered saline (PBS), containing Tween® 80, with and without the addition of mannitol or trehalose. Samples were frozen at -20 °C, freeze-dried and the lyophilised powders were compressed to produce BCG–Eudragit matrices. Production of the dried powders resulted in a reduction in BCG viability. Substantial losses in viability occurred at the initial formulation stage and at the stage of powder compaction. Data indicated that the Eudragit matrix protected BCG against simulated gastric fluid (SGF). The matrices remained intact in SGF and dissolved completely in simulated intestinal fluid (SIF) within three hours. The inclusion of mannitol or trehalose in the matrix provided additional protection to BCG during freeze-drying. Control needs to be exercised over BCG aggregation, freeze-drying and powder compaction conditions to minimise physical damage of the bacterial cell wall and maximise the viability of oral BCG vaccines prepared by dry powder compaction.

Item Type: Article
Divisions : Faculty of Health and Medical Sciences > School of Veterinary Medicine
Authors :
NameEmailORCID
Saleem, Imran
Coombes, Allan G. A.
Chambers, Mark A.m.chambers@surrey.ac.uk
Date : 10 June 2019
Funders : The Department for Environment, Food and Rural Affairs
DOI : 10.3390/pharmaceutics11060270
Copyright Disclaimer : © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Uncontrolled Keywords : BCG; Eudragit; Oral vaccine; Tuberculosis; In vitro viability
Depositing User : Diane Maxfield
Date Deposited : 03 Sep 2019 13:05
Last Modified : 03 Sep 2019 13:05
URI: http://epubs.surrey.ac.uk/id/eprint/852530

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year


Information about this web site

© The University of Surrey, Guildford, Surrey, GU2 7XH, United Kingdom.
+44 (0)1483 300800